News

The development of this drug was originally terminated by Pfizer after a separate clinical trial reported that it increased the risk of death and other adverse cardiovascular outcomes.

The primary aim of the clinical trial was to assess the safety and efficacy of a single dose of AZ-004 in acutely treating agitation in schizophrenic patients. In

As part of a previous agreement, Novartis had produced the multiple sclerosis drug for Bayer. Bayer will now manufacture Betaseron at the site in California and retain full

The study, using ultrasound technology, found that as well as lowering cholesterol Crestor is also effective at halting early changes in the blood vessels that can lead to

The recommendation is based on data from the phase III study which showed that the addition of Herceptin to hormonal therapy doubles the median progression-free survival, from 2.4

Lilly said the new facility would be known as the Lilly-Singapore Center for Drug Discovery and it aims to identify two potential drug candidates from its Singapore center

Under the agreement, EvoGenix utilized its protein optimization technology, EvoGene, to develop improved versions of a protein product from the GSK pharmaceutical pipeline. The protein variants generated had

The phase II trial was designed to assess the long-term safety and outcomes at six months of once or twice weekly infusions of Natrecor compared to placebo in

Patients with high cholesterol were treated for ten weeks with 400 mg/week of the drug ISIS 301012. In this study, increasing the dose of ISIS 301012 to 400